Assisted read study for identifying diabetic eye diseases using an automated detection algorithm

ARDA (Automated Detection Algorithm) assisted read study protocol - Aravind Diabetic Retinopathy Evaluation Software (ADRES) related study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2018/01/011065

Enrollment

1000

Registered

2018-01-01

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: H350- Background retinopathy and retinalvascular changes

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Recruitment of patients from the diabetic clinics which use ADRES (Aravind Diabetic Retinopathy Evaluation Software) grading system. An eligible patient must have a diagnosis of diabetes mellitus.

Exclusion criteria

Exclusion criteria: Non-diabetic patients

Design outcomes

Primary

Measure	Time frame
This programme could be used to screen for diabetic eye disease in peripheral diabetic centresTimepoint: 4-6 months	—

Secondary

Measure	Time frame
The sensitivity and specificity of the software in detecting severe or worse diabetic retinopathy and referrable diabetic macular edema as compared to trained human graders.Timepoint: 4-6 months	—

Countries

India

Contacts

Public ContactDr Varun Gulshan

Google Inc

varungulshan@google.com919818043473

Outcome results